NRG Oncology Researchers Develop Improved Model to Predict Glioblastoma Patients’ Response to Radiation Temozolomide Chemotherapy
A secondary analysis of the clinical trial NRG-RTOG 0525 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients with Newly Diagnosed Glioblastoma or Gliosarcoma was initiated to refine the existing, clinically-based partitioning analysis (RPA) model by incorporating molecular variables. The results of this analysis were published in the Journal of the American Medical Association (JAMA) Oncology on January 12, 2017.
Read the full press release
